Bulk Manufacturer of Controlled Substances Application: ANI Pharmaceuticals, Inc., 47176 [2024-11879]
Download as PDF
<![CDATA[
47176
Federal Register / Vol. 89, No. 106 / Friday, May 31, 2024 / Notices
chromium-coated steel sheet from Japan
would be likely to lead to continuation
or recurrence of material injury to an
industry in the United States within a
reasonably foreseeable time.
Background
The Commission instituted this
review on June 1, 2023 (88 FR 35920)
and determined on September 5, 2023
that it would conduct a full review (88
FR 64464, September 19, 2023). Notice
of the scheduling of the Commission’s
review and of a public hearing to be
held in connection therewith was given
by posting copies of the notice in the
Office of the Secretary, U.S.
International Trade Commission,
Washington, DC, and by publishing the
notice in the Federal Register on
October 30, 2023 (88 FR 74209). The
Commission conducted its hearing on
April 9, 2024. All persons who
requested the opportunity were
permitted to participate.
The Commission made this
determination pursuant to section
751(c) of the Act (19 U.S.C. 1675(c)). It
completed and filed its determination in
this review on May 28, 2024. The views
of the Commission are contained in
USITC Publication 5507 (May 2024),
entitled Tin- and Chromium-Coated
Steel Sheet from Japan: Investigation
No. 731–TA–860 (Fourth Review).
Controlled
substance
Drug code
Psilocybin ...............
Levorphanol ............
By order of the Commission.
Issued: May 28, 2024.
Lisa Barton,
Secretary to the Commission.
I
7437
9220
Schedule
I
I
II
The company plans to bulk
manufacture the listed controlled
substances for the internal use or for
sale to its customers. No other activities
for these drug codes are authorized for
this registration.
[FR Doc. 2024–12014 Filed 5–30–24; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Matthew J. Strait,
Deputy Assistant Administrator.
Drug Enforcement Administration
[FR Doc. 2024–11879 Filed 5–30–24; 8:45 am]
[Docket No. DEA–1365]
BILLING CODE P
Bulk Manufacturer of Controlled
Substances Application: ANI
Pharmaceuticals, Inc.
DEPARTMENT OF JUSTICE
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
Drug Enforcement Administration
ANI Pharmaceuticals, Inc. has
applied to be registered as a bulk
manufacturer of basic class(es) of
controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed
below for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before July 30, 2024. Such persons
Importer of Controlled Substances
Application: Royal Emerald
Pharmaceuticals
AGENCY:
SUMMARY:
khammond on DSKJM1Z7X2PROD with NOTICES
may also file a written request for a
hearing on the application on or before
July 30, 2024.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on April 9, 2024, ANI
Pharmaceuticals, Inc., 70 Lake Drive,
East Windsor, New Jersey 08520,
applied to be registered as a bulk
manufacturer of the following basic
class(es) of controlled substance(s):
VerDate Sep<11>2014
17:22 May 30, 2024
Jkt 262001
listed below for further drug
information.
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before July 1, 2024. Such persons
may also file a written request for a
hearing on the application on or before
July 1, 2024.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on April 10, 2024, Royal
Emerald Pharmaceuticals, 14011 Palm
Drive, Building B, Desert Hot Spring,
California 92240–6845, applied to be
registered as an importer of the
following basic class(es) of controlled
substance(s):
DATES:
[Docket No. DEA–1380]
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Royal Emerald
Pharmaceuticals has applied to be
registered as an importer of basic
class(es) of controlled substance(s).
Refer to SUPPLEMENTARY INFORMATION
SUMMARY:
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
Controlled
substance
Marihuana Extract ..
Marihuana ...............
Tetrahydrocannabinols.
Drug code
7350
7360
7370
Schedule
I
I
I
The company plans to import
Marihuana seeds and immature
Marihuana plants in the form of Active
Pharmaceutical Ingredients (API) and
botanical raw materials for Drug
Enforcement Administration-approved
E:\FR\FM\31MYN1.SGM
31MYN1
]]>Agencies
[Federal Register Volume 89, Number 106 (Friday, May 31, 2024)]
[Notices]
[Page 47176]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-11879]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1365]
Bulk Manufacturer of Controlled Substances Application: ANI
Pharmaceuticals, Inc.
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: ANI Pharmaceuticals, Inc. has applied to be registered as a
bulk manufacturer of basic class(es) of controlled substance(s). Refer
to Supplementary Information listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may submit electronic comments on or
objections to the issuance of the proposed registration on or before
July 30, 2024. Such persons may also file a written request for a
hearing on the application on or before July 30, 2024.
ADDRESSES: The Drug Enforcement Administration requires that all
comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into
the comment field on the web page or attach a file for lengthier
comments. Please go to https://www.regulations.gov and follow the
online instructions at that site for submitting comments. Upon
submission of your comment, you will receive a Comment Tracking Number.
Please be aware that submitted comments are not instantaneously
available for public view on https://www.regulations.gov. If you have
received a Comment Tracking Number, your comment has been successfully
submitted and there is no need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on April 9, 2024, ANI Pharmaceuticals, Inc., 70 Lake
Drive, East Windsor, New Jersey 08520, applied to be registered as a
bulk manufacturer of the following basic class(es) of controlled
substance(s):
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Psilocybin........................... 7437 I
Levorphanol.......................... 9220 II
------------------------------------------------------------------------
The company plans to bulk manufacture the listed controlled
substances for the internal use or for sale to its customers. No other
activities for these drug codes are authorized for this registration.
Matthew J. Strait,
Deputy Assistant Administrator.
[FR Doc. 2024-11879 Filed 5-30-24; 8:45 am]
BILLING CODE P
